Literature DB >> 11511756

Serum interleukin-15 is elevated in systemic lupus erythematosus.

M Aringer1, G H Stummvoll, G Steiner, M Köller, C W Steiner, E Höfler, H Hiesberger, J S Smolen, W B Graninger.   

Abstract

OBJECTIVE: To investigate if interleukin-15 (IL-15) (rather than IL-2) is increased in systemic lupus erythematosus (SLE) and might be responsible for immunological abnormalities of SLE such as the increased lymphocytic expression of Bcl-2 and CD25.
METHODS: Serum IL-15, IL-2 and tumour necrosis factor (TNF) levels of 65 SLE patients, 20 healthy persons and 10 rheumatoid arthritis (RA) patients were measured by enzyme-linked immunosorbent assay (ELISA). For 25 SLE patients, the percentage of CD25 + lymphocytes and the lymphocytic Bcl-2 levels were simultaneously determined by fluorocytometry. Peripheral blood mononuclear cells (PBMC) of 15 SLE patients were incubated with or without recombinant IL-15 and the influence on Bcl-2 and CD25 was determined.
RESULTS: IL-15 was found to be elevated in 25 SLE sera (38%), but in none of the 20 healthy sera (P = 0.0005) and none of the 10 RA sera. Both lymphocyte CD25 and Bcl-2 expression significantly correlated with serum IL-15 and were increased by recombinant IL-15.
CONCLUSION: Serum IL-15 may in part be responsible for the immunological abnormalities seen in active SLE.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11511756     DOI: 10.1093/rheumatology/40.8.876

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  37 in total

Review 1.  Current and novel therapeutics in the treatment of systemic lupus erythematosus.

Authors:  Cagri Yildirim-Toruner; Betty Diamond
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

2.  Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential.

Authors:  Margareta P Correia; Ana Stojanovic; Katharina Bauer; Dilafruz Juraeva; Lars-Oliver Tykocinski; Hanns-Martin Lorenz; Benedikt Brors; Adelheid Cerwenka
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-12       Impact factor: 11.205

3.  The distinct expressions of interleukin-15 and interleukin-15 receptor α in Behçet's disease.

Authors:  Jung-Yoon Choe; Hwajeong Lee; Sang Gyung Kim; Min Ji Kim; Sung-Hoon Park; Seong-Kyu Kim
Journal:  Rheumatol Int       Date:  2013-02-17       Impact factor: 2.631

4.  Natural killer cell expression of Ki67 is associated with elevated serum IL-15, disease activity and nephritis in systemic lupus erythematosus.

Authors:  K Hudspeth; S Wang; J Wang; S Rahman; M A Smith; K A Casey; Z Manna; M Sanjuan; R Kolbeck; S Hasni; R Ettinger; R M Siegel
Journal:  Clin Exp Immunol       Date:  2019-03-19       Impact factor: 4.330

5.  Biomarkers in systemic lupus erythematosus: challenges and prospects for the future.

Authors:  Chau-Ching Liu; Amy H Kao; Susan Manzi; Joseph M Ahearn
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

Review 6.  The dysregulation of cytokine networks in systemic lupus erythematosus.

Authors:  Sokratis A Apostolidis; Linda A Lieberman; Katalin Kis-Toth; José C Crispín; George C Tsokos
Journal:  J Interferon Cytokine Res       Date:  2011-08-30       Impact factor: 2.607

7.  The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity.

Authors:  Linda A Lieberman; George C Tsokos
Journal:  J Biomed Biotechnol       Date:  2010-06-06

Review 8.  CD154 transcriptional regulation in primary human CD4 T cells.

Authors:  Randy Q Cron
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 9.  Brain interleukin-15 in neuroinflammation and behavior.

Authors:  Weihong Pan; Xiaojun Wu; Yi He; Hung Hsuchou; Eagle Yi-Kung Huang; Pramod K Mishra; Abba J Kastin
Journal:  Neurosci Biobehav Rev       Date:  2012-11-29       Impact factor: 8.989

10.  IL-15 maintains T-cell survival via S-nitrosylation-mediated inhibition of caspase-3.

Authors:  P T Saligrama; K A Fortner; M A Secinaro; C C Collins; J Q Russell; R C Budd
Journal:  Cell Death Differ       Date:  2014-02-07       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.